On January 1, 2026, the two-year BioAccess BiH project will be launched as a cooperation initiative between Italy and Bosnia and Herzegovina, with the support of the Autonomous Region of Friuli Venezia Giulia (FVG) – Regional Law 19/2000.
The project, led by Dr Natasa Skoko, Group Leader of Biotechnology Development at ICGEB, brings together key partners: the University of Sarajevo, the Genetic Association in Bosnia and Herzegovina (GENuBiH), the FVG Cluster for Life Sciences, and the ICGEB.
“The goal”, confirms Dr Skoko, “Is to strengthen national capacity in biotechnology and improve access to high-quality biological medicines in Bosnia and Herzegovina.
Senior researchers from the University of Sarajevo will undertake intensive training in Italy on biosimilar production – from genetic modification to the final product. Upon their return to their institute, they will transfer the expertise acquired to colleagues and students, thereby integrating new skills into university programmes and advanced training. This will reach regulatory authorities, health institutions, local pharmaceutical companies, and postgraduate students. “In short,” adds Dr Skoko, “Capacity building and access to biological medicines in Bosnia and Herzegovina aims to integrate scientific evidence into future production practices.”
BioAccess BiH addresses a critical need: Bosnia and Herzegovina currently relies on imported biologics such as filgrastim, an essential drug for cancer patients, due to the absence of local production capacity. While biosimilars have reduced costs globally by up to 70%, their use in the country remains limited. By enabling local researchers to replicate and adapt biosimilar manufacturing processes, the project will open the door to new technological development, applied research, and pilot production.
The project will lay the foundation for sustainable biosimilar production in Bosnia and Herzegovina and further strengthen the long-term partnership between collaborating institutions and the FVG Region.
